Ora

The Ophthalmology Research Company™

Turning complex science into meaningful outcomes

At Ora, ophthalmic research is all we do. With 50+ years of growth and experience running ophthalmology clinical trials, our proven success, global reach, and passion to drive ophthalmic innovation sets us apart from our competitors. Our singular focus on ophthalmology allows us to deeply understand the unique challenges and opportunities associated with each ocular indication.

85+
Product approvals

3,000+
Programs supported

20+
Currently active countries

Our foundational principle at Ora is to provide ophthalmic expertise and experience at every level across every stage of the process. We support our partners from concept to approval.

End-to-end ophthalmic support

Ora specializes exclusively in ophthalmology, guiding therapies from preclinical development to regulatory approval and beyond.

Expertise & efficiency

With deep therapeutic knowledge and experience in early-phase and pivotal trials, Ora accelerates timelines, mitigates risks, and ensures high-quality data.

Strategic partnership

Partnering with Ora provides access to a trusted team dedicated to overcoming ophthalmic development challenges and driving program success.

Therapeutic experience highlights



Ophthalmic knowledge makes the difference in complex trial execution

Deep subspeciality experience

Optimizes protocol and processes specifically for your program

Close site relationships

Get your trial prioritized at the right sites for reaching the right patients

Tenured operations experts

Continually finding ways to streamline processes and speed up time to data lock

Unmatched knowledge of ophthalmic diseases and patients

Optimizes site training and accelerates enrollment

Competitive intelligence built Into every study execution

Avoids competitive site conflicts and maximizes timelines

A sample of Ora successes:

End-to-end ophthalmology therapeutic pipeline highlights over the last 5 years

Cornea & Ocular Surface

Proven track record of success with 60+ product approvals. Most recently, provided turnkey support for the innovative DED therapeutic VEVYE®, which was approved by the FDA in May 2023.

11,000+
Patients Recruited

190+
Programs

Retina & Macular Diseases

A recent DME drug approval by the FDA in 2023 [novel decoy receptor that binds VEGF-A], showcasing Ora's ability to guide Retina & Macular Disease therapeutics from concept to approval.



1,450+
Patients Recruited

130+
Programs

Cataracts & Refractive

Ora's partnership with innovators has been instrumental in bringing a novel intraocular lens, a contact lens–therapeutic combination treatment, and a Presbyopia therapeutic successfully from development to market.



3,200+
Patients Recruited

60+
Programs

Glaucoma & Optic Neuropathies

Proven track record of success with 10+ Glaucoma products on the current market that were delivered with the help of Ora clinical trials and/or regulatory support.

775+
Patients Recruited

20+
Programs

Inflammatory & Autoimmune

Accelerated enrollment for two patient populations (naïve & treatment experienced) 1.5 and 3 months ahead of schedule in a global Phase 2 Thyroid Eye Disease program.

200+
Patients Recruited

7
Programs

Extensive global reach for diverse ophthalmic studies



Why choose Ora for global ophthalmology clinical trials?

Global trial experience

Over 3,000 ophthalmic projects completed around the world. Our local teams around the globe have the experience you need for successful product development.

Robust global network

Over 400+ close site partnerships with track record of program delivery. Extensive globally influential KOL partnership network with vast Phase 2 & 3 trial experience.

Highly tenured execution specialists

Ora has 90%+ study staff retention rates, compared to <80% for the average CRO.

Innovative strategies

Our R&D team is continually developing cutting-edge clinical trial innovations, endpoints, and approaches to analyze and interpret data. Over 60% of Ora studies use these tools to accelerate timelines and improve data quality.

Proven track record

On average, our PMs have 12+ years of ophthalmic experience and have successfully managed 10+ ophthalmic clinical trials.

Ora® The Ophthalmology Research Company™

With over 50 years of ophthalmic clinical research expertise, we approach each project not just with meticulous planning, but with a genuine commitment to excellence, innovation, & success.

Research with confidence

As the trusted full-service CRO of ophthalmic innovators around the globe, we're ready to support your research goals on the pathway to approval.

Scan to reach our team and take the first step in exploring a partnership.

Learn more about what we do at OraClinical.com +1 (978) 685-8900